New developments in sustained release drug delivery for the treatment of intraocular disease.
Velez
G
G
National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Whitcup
S M
SM
D000998:Antiviral Agents / Q000627:therapeutic use; D018916:Blood-Aqueous Barrier; D016572:Cyclosporine / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005128:Eye Diseases / Q000188:drug therapy; D015774:Ganciclovir / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D012164:Retinal Diseases / Q000188:drug therapy*; D014822:Vitreous Body
D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D004343:Drug Implants; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D015774:Ganciclovir